Key Takeaway: Vir Biotechnology, Inc. will host a conference call on May 6, 2026, at 4:30 p.m. ET to discuss its financial results for the first quarter ending March 31, 2026. The call will provide a corporate update and can be accessed via the company's website. Vir is focused on developing treatments for infectious diseases and cancer.
Price reaction · baseline $10.67 (2026-04-22 close) · hit after-hours · clean, no other VIR news in the window
day 0 close · peak
-3%
Market Sentiment Analysis
POSITIVE FACTORS
Vir Biotechnology is actively engaging with investors through a conference call.
The company is focused on innovative treatments for serious diseases.
Vir has a diverse clinical-stage portfolio addressing significant health issues.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
14%
average across 4 past catalysts
Lead asset
Tobevibart
Phase 3 · Viral Hepatitis
Full Press Release Details
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial results for the first quarter ended March 31, 2026. The conference call may be accessed on theEvents & Presentationspage of the Vir Biotechnology website.
About Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN®dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Vir Biotechnology retains exclusive rights to the PRO-XTEN®masking platform for oncology and infectious disease. PRO-XTEN®is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
Frequently Asked Questions
When is Vir Biotechnology's conference call?
The conference call is scheduled for May 6, 2026, at 4:30 p.m. ET.
What will be discussed in the conference call?
The call will cover Vir's financial results for the first quarter of 2026.
How can I access the conference call?
The conference call can be accessed on the Events & Presentations page of Vir's website.
What is Vir Biotechnology focused on?
Vir Biotechnology focuses on developing treatments for infectious diseases and cancer.